CycA-Dependent Glycine Assimilation Is Connected to Novobiocin Susceptibility in Escherichia coli

Shi, Hongmei; Zhang, Ling; Gu, Jing; Li, Jinyue; Liu, Zixiang; Deng, Jiao-Yu

doi:10.1128/spectrum.02501-22

Cited by 1 publication

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, 4-hydroxycoumarin anticoagulants typified by warfarin inhibit the function of vitamin K and exert the anticoagulant activity [ 31 ]. Aminocoumarin antibiotic Novobiocin inhibits bacterial DNA gyrase and heat shock protein in cancer cells and is used as an antibacterial and anticancer agent [ 32 , 33 ]. Meanwhile, the pharmaceutical properties and toxicity of the coumarins vary significantly based on their specific chemical structure; it was reported that coumarin derivatives could induce hepatocellular dysfunction and possessed an inhibitory effect on human CYP enzymes [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

Pharmacological Characters and Toxicity Evaluation of Coumarin Derivative LP4C as Lead Compound against Biofilm Formation of Pseudomonas aeruginosa

Xin

Liu

et al. 2023

Molecules

View full text Add to dashboard Cite

Pseudomonas aeruginosa-induced biofilm infection is difficult to treat and poses a significant threat to public health. Our previous study found a new coumarin derivative LP4C which exerted potent in vitro and in vivo anti-biofilm activity against Pseudomonas aeruginosa; however, the underlying molecular mechanism and drug-likeness of LP4C is unclear. In this study, we confirmed that LP4C could inhibit the biofilm in dose-dependent manner without bactericidal activity. The transcriptomic profiling and RT-PCR result revealed that bacterial pyrimidine mediated the inhibitory activity of LP4C. The cell viability was not affected in LP4C treatment groups with the concentration under 200 μg/mL, and no death or toxicity sign was observed in mice treated by 20, 40 and 80 mg/kg LP4C during the three-week test period. Ames test presented that LP4C had no effect on the bacterial reverse mutation. In additional, pharmacokinetic results showed that LP4C was likely to have the orally bioavailable properties. Our data indicate that LP4C is a possible lead compound for the development of new anti-biofilm infection agents against Pseudomonas aeruginosa.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacological Characters and Toxicity Evaluation of Coumarin Derivative LP4C as Lead Compound against Biofilm Formation of Pseudomonas aeruginosa

Xin

Liu

et al. 2023

Molecules

View full text Add to dashboard Cite

show abstract

CycA-Dependent Glycine Assimilation Is Connected to Novobiocin Susceptibility in Escherichia coli

Abstract: Novobiocin (NOV) has been used in clinical practice as an ATPase inhibitor for decades. However, because it has been withdrawn from the market, pharmaceutical companies are searching for other ATPase inhibitors.

Cited by 1 publication

References 35 publications

Pharmacological Characters and Toxicity Evaluation of Coumarin Derivative LP4C as Lead Compound against Biofilm Formation of Pseudomonas aeruginosa

Pharmacological Characters and Toxicity Evaluation of Coumarin Derivative LP4C as Lead Compound against Biofilm Formation of Pseudomonas aeruginosa

Contact Info

Product

Resources

About